Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Biran, Noa [1 ]
Vesole, David H. [1 ]
Zhang, Shijia [2 ]
Richter, Joshua R. [1 ]
Kuo, Yen-Hong [3 ]
Schmidt, Linda [1 ]
McBride, Laura [1 ]
Anand, Palka [1 ]
Ivanovski, Kristin [1 ]
Pierre, Amy
Kumka, Susan [1 ]
Cuccurullo, Carmela [1 ]
Siegel, David S. [1 ]
机构：
[1] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Rutgers New Jersey Med Sch, Dept Med, Newark, NJ USA
[3] Jersey Shore Univ Med Ctr, Dept Res, Neptune, NJ USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.5685.5685
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5685
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma
    Mark, Tomer
    Falkenstein, Angelica
    Kish, Jonathan
    FUTURE ONCOLOGY, 2022, 18 (05) : 553 - 564
  • [22] Real-World Outcomes for the Treatment of Relapsed/Refractory Multiple Myeloma With Daratumumab: A Systematic Literature Review
    Gros Otero, B.
    Gungor, G.
    Gruppe, T. L.
    Wan, M.
    Jenkins, C.
    Helme, K.
    VALUE IN HEALTH, 2022, 25 (12) : S494 - S494
  • [23] Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma (RRMM): A Real-World Analysis
    Dong, Sharlene
    Banerjee, Rahul
    Khan, Adeel
    Wang, Mengru
    Wang, Xiaoliang
    Afghahi, Anosheh
    Afrough, Aimaz
    Janakiram, Murali
    Wang, Bo
    Cowan, Andrew
    Sperling, Adam
    Anderson, Larry
    Rajkumar, S. Vincent
    Kaur, Gurbakhash
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S258 - S259
  • [24] Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma
    Greig, Sarah L.
    TARGETED ONCOLOGY, 2016, 11 (01) : 107 - 114
  • [25] Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma
    Sarah L. Greig
    Targeted Oncology, 2016, 11 : 107 - 114
  • [26] Real-world treatment patterns and outcomes in lenalidomide refractory multiple myeloma patients in Europe: a real-world survey
    Martinez-Lopez, Joaquin
    Mendes, Joao
    Luke, Emily
    Kluth, Caspian
    Salmon, Phoebe
    Bailey, Abigail
    Ribbands, Amanda
    Gay, Francesca
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S198 - S199
  • [27] Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab
    Richter, Joshua
    Anupindi, Vamshi Ruthwik
    Yeaw, Jason
    Kudaravalli, Suneel
    Zavisic, Stojan
    Shah, Drishti
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (02) : 395 - 409
  • [28] DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD
    Romanus, D.
    Raju, A.
    Yong, C.
    Seal, B.
    Farrelly, E.
    Noga, S.
    Jhaveri, M.
    Labotka, R.
    Blazer, M.
    Parameswaran, H.
    HAEMATOLOGICA, 2016, 101 : 538 - 539
  • [29] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
    Hultcrantz, Malin
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Maclachlan, Kylee H.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Akhlaghi, Theresia
    Hamadeh, Issam S.
    Chung, David J.
    Lahoud, Oscar B.
    Landau, Heather
    Scordo, Michael
    Shah, Gunjan L.
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Usmani, Saad
    BLOOD, 2022, 140 : 7246 - 7248
  • [30] A German Multicenter Real-World Analysis of Talquetamab in 102 Patients With Relapsed/ Refractory Multiple Myeloma
    Frenking, Jan
    Riedhammer, Christine
    Besemer, Britta
    Braune, Jan
    Brioli, Annamaria
    Brunner, Franziska
    Dampmann, Maria
    Gezer, Deniz
    Goldman-Mazur, Sarah
    Haenel, Mathias
    Hanoun, Christine
    Hoegner, Marion
    Kolditz, Katja
    Kos, Igor
    Kull, Miriam
    Leitner, Theo
    Merz, Maximilan
    von Metzler, Ivana
    Michel, Christian S.
    Teipel, Raphael
    Theurich, Sebastian
    Waesch, Ralph
    Zukovs, Romans
    Rasche, Leo
    Raab, Marc-Steffen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S52 - S53
12345